Last updated on March 2019

A Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Patients With Narcolepsy

Brief description of study

The purpose of this study is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-925 when administered to healthy participants and narcolepsy patients.

Detailed Study Description

The drug being tested in this study is called TAK-925. TAK-925 is being tested in healthy participants and patients with narcolepsy. This study will look at the safety, tolerability, pharmacokinetics, and efficacy of TAK-925.

This study will consist of three parts. Part A will be a randomized, double-blind, placebo-controlled, multiple rising dose (MRD) study in healthy participants. Part B is a randomized, double-blind, placebo-controlled MRD study in patients with narcolepsy. Part C is a randomized, double-blind, placebo-controlled, parallel group, multiple repeat dose study in patients with narcolepsy.

The study will enroll approximately 84 participants planned as total. All participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groupswhich will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):

Part A study;

  • TAK-925 (Dose Levels A1-A6)
  • Placebo Part B study;
  • TAK-925 (Dose Levels B1-B4)
  • Placebo Part C study;
  • TAK-925 (Dose Levels C1-C2)
  • Placebo

All participants will be asked to take TAK-925 or Placebo at the same time each day from Day 1 to Day 7.

This multi-center trial will be conducted in Japan. The overall study period is 15 days. Participants will be partly admitted to a hospital during the study.

Clinical Study Identifier: NCT03748979

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.